Registrieren Sie sich, um Meldungen für Instrumente,
Wirtschaftsevents und Inhalte von Autoren zu erhalten, denen Sie folgen
Gratis registrieren Sie haben bereits ein Benutzerkonto? Anmelden
Kurse
Alle Finanzinstrumente
- Alle Finanzinstrumente
- Indizes
- Aktien
- ETFs
- Fonds
- Rohstoffe
- Währungen
- Krypto
- Anleihen
- Zertifikate
Versuchen Sie es noch einmal mit einem anderen Suchbegriff
🐂 Anfang November von unserer KI ausgewählt: Diese 5 Aktien haben jetzt schon über 20% zugelegt!
Aktien ansehen
Eventide Healthcare & Life Sciences Fund Class A Shares (ETAHX)
Einem Portfolio hinzufügen/entfernen
Portfolio hinzufügen
34,52
-0,82
-2,32%
14/11 - Zeitverzögert. Währung in USD
- Morningstar Rating:
- Aktiva (gesamt): 119,06M
Eventide Healthcare & Life Sciences A
34,52
-0,82
-2,32%
ETAHX Übersicht
Auf dieser Seite finden Sie ein ausführliches Eventide Healthcare & Life Sciences Fund Class A Shares Profil. Erfahren Sie mehr über das Management, das Gesamtvermögen, die Anlagestrategie und die ETAHX Kontaktinformationen.
Kontaktinformation
Management
| Name | Titel | Seit | Bis |
|---|---|---|---|
| I-hung Shih | Portfolio Manager | 2024 | Aktuell |
| Biografie | I-hung Shih, PhD, Biochemistry, joined Eventide in July 2024 and has led Eventide’s Healthcare team as Managing Director and Co-Portfolio Manager since September 2024 under the supervision of the Adviser’s Co-Chief Investment Officers. Effective September 1, 2024, Dr. Shih will be a Managing Director for Eventide Ventures®, Eventide's private investing line of business. Dr. Shih has over 20 years of professional experience. Before starting at Eventide she was Portfolio Manager and a Global Industry Analyst before being promoted as Co-Head of Wellington Biotech Private Investments at Wellington Management Company. Prior to her time at Wellington, Dr. Shih held investment management roles on teams at T.Rowe Price, Temasek International, and Credit Suisse. She began her career in research, working as a Research Fellow at the NIH and Whitehead Institute at MIT. Following those experiences, she joined Gilead Sciences where she started as a Research Scientist, and then worked as a Senior Manager in Commercial Strategy, before entering the investment management industry. Dr. Shih holds a PhD in Biochemistry from Duke University. She also holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Chemistry from the National Taiwan University. | ||
| Finny Kuruvilla | Resident | 2012 | Aktuell |
| Biografie | Finny Kuruvilla, MD, PhD, serves as a Co-Chief Investment Officer, Senior Portfolio Manager for Eventide’s mid-cap growth and healthcare & life sciences strategies, a Managing Director for Eventide’s private fund, as well as Founding Member of Eventide. Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech. | ||
| Kyle Rasbach | Portfolio Manager | 2023 | 2024 |
| Biografie | Kyle Rasbach, PhD, PharmD, joined Eventide in April 2022, and has led Eventide’s Healthcare team across all Eventide Investment products since June 2022 under the supervision of the Adviser’s Co-Chief Investment Officers. Dr. Rasbach has served as a Managing Director for the Eventide Healthcare Innovation Fund I, LP, since November 2022. Dr. Rasbach has extensive experience in clinical pharmacology, basic science, and healthcare equity research. Prior to joining Eventide, Dr. Rasbach was a Managing Partner at Pappas Capital, a life science venture capital firm that invests across biotechnology, biopharmaceuticals, drug delivery, and medical devices, from 2017-2022. Earlier in his career he was an equity research analyst and Vice President at T. Rowe Price from 2013-2017, where he managed pharmaceutical, specialty pharmaceutical, and biotechnology investments. Prior to joining T. Rowe Price, Dr. Rasbach was an equity research associate and Vice President at Cowen and Company from 2010-2013, where he covered global pharmaceutical equities. Dr. Rasbach holds a PhD in Pharmaceutical and Biomedical Sciences as well as a PharmD from the Medical University of South Carolina; he completed his postdoctoral training in the laboratory of Bruce Spiegelman at the Harvard Medical School. He also holds an MBA from The Citadel and a BS in Biology from Denison University. | ||
| Joy Ghosh | Portfolio Manager | 2022 | 2022 |
| Biografie | Dr. Joy Ghosh has served the Adviser as a Portfolio Manager since January 2022 and Senior Analyst since 2020. Prior to joining the Adviser, Dr. Ghosh was Vice President of Bain Capital from 2019 to 2020 and an Associate of Bain Capital from 2017 to 2019. Dr. Ghosh holds a PhD from the University of Washington, Seattle in Biomolecular Structure and Design and a bachelor’s degree in Biochemistry from the University of Texas at Austin. | ||
Was denken Sie über Eventide Healthcare & Life Sciences Fund Class A Shares
Sind Sie sicher, dass Sie diesen Chart löschen möchten?
Löschen Abbrechen
Angehängten Chart durch einen neuen Chart ersetzen?
Ersetzen Abbrechen
Community-Richtlinien
Chart zum Kommentar hinzufügen
Sperre bestätigen
Sind Sie sicher, dass Sie %USER_NAME% sperren möchten?
Dadurch werden Sie und %USER_NAME% nicht mehr in der Lage sein, Beiträge des jeweils anderen auf Investing.com zu sehen.
%USER_NAME% wurde erfolgreich zu Ihrer Sperrliste hinzugefügt.
Da Sie diese Person entsperrt haben, müssen Sie 48 Stunden warten, bevor Sie sie wieder sperren können.
Diesen Kommentar melden
Sagen Sie uns Ihre Meinung zu diesem Kommentar
Kommentar markiert
Vielen Dank!
Ihre Meldung wurde zur Überprüfung an unsere Moderatoren geschickt